Olema Pharmaceuticals (OLMA) Cash & Equivalents (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Cash & Equivalents data on file, last reported at $52.5 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 3.77% year-over-year to $52.5 million in Q1 2026; TTM through Mar 2026 was $52.5 million, a 3.77% increase from a year earlier, with the FY2025 full-year figure at $48.3 million, down 65.37% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $52.5 million, up from $48.3 million in the prior quarter.
• Over the last five years, Cash & Equivalents for OLMA reached as high as $139.5 million in Q4 2024 and fell as low as $16.9 million in Q2 2024.
• Historically, Cash & Equivalents has averaged $48.4 million across 5 years, with a median of $35.9 million in 2024.
• Across the five-year window, Cash & Equivalents jumped 338.02% in 2023 and sank 69.43% in 2024, its largest moves.
• Year by year, Cash & Equivalents stood at $23.7 million in 2022, then soared by 189.17% to $68.5 million in 2023, then soared by 103.5% to $139.5 million in 2024, then tumbled by 65.37% to $48.3 million in 2025, then rose by 8.79% to $52.5 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $52.5 million in Q1 2026, $48.3 million in Q4 2025, and $35.3 million in Q3 2025.